BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 32331305)

  • 1. Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse.
    Carvalho ACA; Souza GA; Marqui SV; Guiguer ÉL; Araújo AC; Rubira CJ; Goulart RA; Flato UAP; Bueno PCDS; Buchaim RL; Barbalho SM
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of cannabis based treatment in Crohn's disease.
    Naftali T
    Expert Rev Gastroenterol Hepatol; 2020 Apr; 14(4):253-257. PubMed ID: 32149543
    [No Abstract]   [Full Text] [Related]  

  • 3. Cannabis for the Treatment of Crohn's Disease and Ulcerative Colitis: Evidence From Cochrane Reviews.
    Kafil TS; Nguyen TM; MacDonald JK; Chande N
    Inflamm Bowel Dis; 2020 Mar; 26(4):502-509. PubMed ID: 31613959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
    Hasenoehrl C; Storr M; Schicho R
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):329-337. PubMed ID: 28276820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabis use amongst patients with inflammatory bowel disease.
    Lal S; Prasad N; Ryan M; Tangri S; Silverberg MS; Gordon A; Steinhart H
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):891-6. PubMed ID: 21795981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabis for inflammatory bowel disease.
    Naftali T; Mechulam R; Lev LB; Konikoff FM
    Dig Dis; 2014; 32(4):468-74. PubMed ID: 24969296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians.
    Buckley MC; Kumar A; Swaminath A
    Adv Ther; 2021 Jul; 38(7):4152-4161. PubMed ID: 34110607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging immunological targets in inflammatory bowel disease.
    Monteleone G; Pallone F; MacDonald TT
    Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study.
    Naftali T; Bar-Lev Schleider L; Dotan I; Lansky EP; Sklerovsky Benjaminov F; Konikoff FM
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1276-1280.e1. PubMed ID: 23648372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the Use of Curcumin on Ulcerative Colitis and Crohn's Disease: A Systematic Review.
    Goulart RA; Barbalho SM; Lima VM; Souza GA; Matias JN; Araújo AC; Rubira CJ; Buchaim RL; Buchaim DV; Carvalho ACA; Guiguer ÉL
    J Med Food; 2021 Jul; 24(7):675-685. PubMed ID: 33155879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terpenes: Modulating anti-inflammatory signaling in inflammatory bowel disease.
    Rivera Rodríguez R; Johnson JJ
    Pharmacol Ther; 2023 Aug; 248():108456. PubMed ID: 37247693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
    Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
    Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonenzymatic Serum Antioxidant Capacity in IBD and Its Association with the Severity of Bowel Inflammation and Corticosteroids Treatment.
    Neubauer K; Kempinski R; Matusiewicz M; Bednarz-Misa I; Krzystek-Korpacka M
    Medicina (Kaunas); 2019 Apr; 55(4):. PubMed ID: 30986917
    [No Abstract]   [Full Text] [Related]  

  • 14. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polyphenols in the treatment of inflammatory bowel diseases].
    Chojnacka K; Laskowska J
    Postepy Biochem; 2020 Sep; 66(3):256-262. PubMed ID: 33315320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
    Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
    Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets.
    Stefanelli T; Malesci A; Repici A; Vetrano S; Danese S
    Curr Drug Targets; 2008 May; 9(5):413-8. PubMed ID: 18473770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of integrin antagonists in the treatment of inflammatory bowel disease.
    Beniwal-Patel P; Saha S
    Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse.
    Hansen TM; Sabourin BC; Oketola B; Bernstein CN; Singh H; Targownik LE
    Inflamm Bowel Dis; 2020 Aug; 26(9):1401-1406. PubMed ID: 31725152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.